Video Experimental Relacionado

Updated: Feb 6, 2026

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

Baricitinib desencadenando una enfermedad inflamatoria desmielinizante del sistema nervioso central: reporte de un

Rozita Khalili^1,2, Ahmad A Toubasi², Meryim Poursheykhi³

¹Neuroimmunology Division, Department of Neurology, University of Tennessee Health Science Center (UTHSC), Memphis, TN, USA.

Multiple sclerosis journal - experimental, translational and clinical

|February 5, 2026

Resumen

Los inhibidores de Janus quinasa (JAKis), como el baricitinib, pueden reducir la inflamación pero desencadenar enfermedades desmielinizantes del sistema nervioso central (SNC). Este caso destaca el riesgo potencial de que el baricitinib exacerbe la inflamación del SNC, lo que requiere una monitorización cuidadosa del paciente.

Área de la Ciencia:

Inmunología
Neurología
Farmacología

Sus antecedentes:

Los inhibidores de Janus quinasa (JAKis) modulan las vías inflamatorias.
Los JAKis se utilizan para tratar afecciones inflamatorias.
Informes anteriores relacionaron un JAKi (tofacitinib) con enfermedades desmielinizantes del SNC.

Objetivo del estudio:

Reportar el primer caso de enfermedad desmielinizante inflamatoria del sistema nervioso central (SNC) posiblemente exacerbada por baricitinib.
Concienciar sobre los posibles efectos adversos neurológicos del baricitinib.

Principales métodos:

Presentación de un reporte de caso.
Revisión de la historia clínica del paciente y el curso del tratamiento.
Discusión del papel potencial del baricitinib en la exacerbación de la inflamación del SNC.

Principales resultados:

Se describe un caso de enfermedad desmielinizante inflamatoria del SNC potencialmente relacionada con el uso de baricitinib.
Este evento ocurrió a pesar de los efectos antiinflamatorios previstos del baricitinib.

Conclusiones:

El baricitinib, un inhibidor de Janus quinasa, puede estar asociado con la exacerbación de enfermedades desmielinizantes inflamatorias del SNC.
La mayor vigilancia clínica y la monitorización estrecha son cruciales para los pacientes en terapia con JAKi, incluido el baricitinib.

Palabras clave:

inhibidor de Janus quinasa baricitinib sistema nervioso central enfermedades inflamatorias desmielinizantes

Más Videos Relacionados

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Videos de Conceptos Relacionados

Inflammatory Bowel Disease II: Crohn's Disease

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...

What is a Nervous System?

What is a Nervous System?

Inflammatory Bowel Disease I: Ulcerative Colitis

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

Inflammatory Bowel Disease V: Surgical Management

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Measures of Central Tendency

Measures of Central Tendency

The "center" of a data set is also a way of describing location. The two most widely used measures of the "center" of the data are the mean (average) and the median. The words "mean" and "average" are often used interchangeably. The substitution of one word for the other is common practice. The technical term is "arithmetic mean" and "average" is technically a center location. However, in practice among non-statisticians,...